Related Experiment Videos
Local control versus dose or overall time: from coefficients to percentages
1Department of Human Oncology, University of Wisconsin Medical School, Madison 53792.
The British Journal of Radiology
|November 1, 1994
Summary
Multivariate analysis of clinical results identifies key treatment variables affecting outcomes. Converting coefficients into understandable "percent change" metrics offers clearer insights into treatment effects on local control.
Area of Science:
- Oncology
- Radiation Therapy
- Biostatistics
Background:
- Multivariate analysis is crucial for understanding treatment variables impacting clinical outcomes.
- Current methods often present coefficients in raw or ratio forms, limiting direct interpretation.
Purpose of the Study:
- To explore a more interpretable method for presenting multivariate analysis coefficients.
- To convert statistical coefficients into clinically meaningful "percent change" metrics.
Main Methods:
- Utilized multivariate analysis to identify significant variables (e.g., age, gender, dose) influencing local control.
- Developed a quasi-biological model (e.g., Function (p) = Variable 1 + Variable 2 + ... + alpha x dose + beta x dose x (dose per fraction) - gamma x (overall time)) to quantify variable effects.
- Mathematically converted raw coefficients (alpha, gamma) into "percent change in local control per unit" metrics.
Main Results:
- Demonstrated the mathematical possibility of converting coefficients into "percent change" values for dose and time.
- These converted values represent the rate of change in local control under specific variable conditions.
- Acknowledged that heterogeneity can alter slopes, but converted values still provide valuable group-averaged insights.
Conclusions:
- Converting coefficients to "percent change" offers a more understandable interpretation of treatment variable impact on local control.
- This approach enhances clinical insight by providing direct, interpretable measures of treatment effects.
- The findings are applicable even when accounting for biological heterogeneity in patient groups.